L4 22K Polypeptide for AAV Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing adenoviral vectors, particularly AAV vectors, face challenges such as the need to separate adenovirus particles, low yields, and inefficiencies in transfection processes, which hinder the production of high-quality AAV particles while also producing unwanted adenoviral particles.
Innovation Solution
The method involves culturing host cells with a CARE element operably-linked to a DNA molecule, using a L4 22K polypeptide to amplify AAV Rep and Cap genes, thereby increasing expression levels of AAV particles while inhibiting adenoviral particle production by regulating adenoviral Late gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If adenoviral vectors are used to produce AAV vectors, then AAV production is facilitated, but adenoviral particles are co-produced requiring separation
Solution Approach 1:
The invention extracts and utilizes only the specific L4 22K polypeptide function from the adenoviral system while removing the harmful co-production of adenoviral particles. By using a heterologous promoter to drive L4 22K expression independently of adenoviral replication, the system obtains the beneficial AAV amplification effect without the harmful adenoviral particle contamination that would require separation processes.
Solution Approach 2:
The L4 22K polypeptide acts as an intermediary that mediates AAV genome amplification without requiring full adenoviral particle production. The heterologous promoter system serves as an intermediary mechanism to express the essential L4 22K function while decoupling it from the harmful adenoviral replication cycle, thereby facilitating AAV production without generating unwanted adenoviral particles.
2Productivity
If traditional transfection methods are used, then AAV vectors can be produced, but yields are low and processes are inefficient
Solution Approach 1:
The invention employs preliminary action by stably integrating the L4 22K expression cassette into the host cell genome before AAV production. This stable integration ensures that the L4 22K polypeptide is constitutively expressed and readily available to amplify AAV genomes during infection, eliminating the need for inefficient transfection steps and significantly improving productivity.
Solution Approach 2:
The invention changes the expression parameter of L4 22K from transient (via transfection) to stable (via genomic integration). This parameter change ensures continuous, high-level expression of the amplification factor, thereby increasing AAV yields and improving process efficiency by eliminating repeated transfection operations.
3Quantity of substance
If adenoviral Late genes are expressed, then AAV amplification occurs, but adenoviral particle production increases
Solution Approach 1:
The invention extracts the specific function of L4 22K polypeptide in AAV amplification while removing it from the context of full adenoviral Late gene expression and particle production. By placing L4 22K under a heterologous promoter, the system obtains the beneficial amplification effect without the harmful byproduct of adenoviral particle assembly.
Solution Approach 2:
The invention converts the potentially harmful full adenoviral replication process into a beneficial selective expression system. By using a heterologous promoter to drive only L4 22K expression, the system harnesses the amplification capability that would normally accompany harmful adenoviral particle production, while eliminating the harmful aspect through selective gene expression.
Data Source
AI summary
The present invention relates to a method of amplifying a DNA molecule which is operably-linked to a CARE element in a host cell. The method comprises the step of culturing a host cell which comprises a CARE element operably-linked to the DNA molecule, a nucleotide sequence encoding a L4 22K polypeptide or a variant thereof, a nucleic acid molecule comprising a nucleotide sequence encoding an AAV Rep polypeptide or a variant thereof, and optionally one or more further nucleic acid molecules. The invention also relates to nucleic acid molecules encoding a L4 22K polypeptide or a variant thereof, operably-linked to a heterologous promoter; nucleic acid molecules encoding a CARE element operably-linked to viral genes; processes for producing adenoviral vectors and host cells; and processes for producing viral particles, more preferably AAV particles, in host cells.